Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer
Stock Up By 87.9%
Executive Summary
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.